3Sager JW, Gutteridge C, Syndercombe-Court D, et al. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coil Cardiol, 1998, 32(7): 1962 - 1968.
4Sarkar R,Misra A,Saxena R,et al. PLasma plasminogen activator inhibitor-1 actiivity in normoglycemic hypertriglyceridemidc north Asian Indian Subject: a preliminary case-control study. Indian Heart J ,2001,53(1) :61-65.
5Koistinen H A, Dusserre E. Ebeling p, et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type2 diabetic subjects. Diabetes Metab Res Rev, 2000,(615):364-369.
6gottschling-Zeller H,Birgel M,Rohrig K,et al. Effect of tumor necrosis factor alpha and transforming growth factor betal on plasminogen activator inhibitor-1 secretion from subcutaneous and omental fat cells in suspension culture. Metabolism, 2000,49 (5) : 666 - 671.
7Morange PE, Aubert J, Peiretti F, et al. Glucocorticoids and insulin promote plasminogen activator inhibitorl production by human adipose tissue. Diabetes, 1999,48 ( 4 ) : 890 - 895.
8Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen Inhibitorl and insulin resistance. Diabetes Metab Res Rev,2000,16(3) : 192-201.
9Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAl-1 are linked to atherothrombosis via insulin resistance and obesity. Ann-Med, 2000,32 (suppl) : 178-184.
10Alessi MC, Morange PE,Juhan-Vagve I. Fat cell function and fibrinolysis. Horm-Metab-Res, 2000,32 ( 11 - 12 ) : 504-508.
